Shield Therapeutics has reported FY24 results in line with our expectations for revenues and ahead of expectations at the bottom line, reflecting strong gross margins and effective management of overheads. The company’s recent news flow has also seen expansion of the global footprint (ACCRUFeR® launch in Canada) which forms part of the wider arc of the story. Investors will be alert to the challenges related by the 1Q25 commentary, released last week, with the period impacted primarily by weathe ....
